Assessment of mean platelet volume in chronic obstructive pulmonary disease during stable period and acute exacerbation

Abstract

Objective: Chronic obstructive pulmonary disease (COPD) is an important public health problem and it is associated with systemic inflammation. Mean platelet volume (MPV) is one of the markers indicating platelet activation, and it was found to be high in many diseases related to inflammation. In previous studies reported different results evaluating of MPV in COPD. In this study, we aimed to evaluate of C-reactive protein (CRP), white blood cell (WBC), and MPV in acute exacerbation of COPD and stable COPD patients. Methods: In this retrospective study, data of 40 patients with acute exacerbation of COPD, 43 stable COPD patients and 40 healthy subjects were evaluated. Results: The mean MPV, CRP and WBC were found in control, stable COPD and acute exacerbation of COPD groups, 7.9±1.1; 8.2±1.3 and 8.7±1.6 fL; 3.4±1.2; 5.2±3.5 and 27.5±23.6 mg/L; 7.8±1.6; 8.1±2.1 and 11.4±4.5 x103/ ϻL, respectively. The mean WBC and CRP in the acute exacerbation of COPD group were significantly higher than the other groups (for both values p ˂0.001). The mean MPV in the acute exacerbation of COPD group was found higher than in the other groups. The mean MPV values were significantly higher in patients of acute exacerbation than control subjects (p=0.030). Conclusion: The results of this study suggest that the increased MPV may be a marker for the evaluation acute exacerbation of COPD as well as the classic acute phase reactant CRP. J Clin Exp Invest 2013; 4 (4): 483-487

Keywords

• Chronic obstructive pulmonary disease, complete blood count, C-reactive protein, mean platelet volume

Kronik obstrüktif akciğer hastalığının akut alevlenme ve stabil dönemlerinde ortalama trombosit hacminin incelenmesi

Öz

Amaç: Kronik Obstrüktif Akciğer Hastalığı (KOAH) önemli bir halk sağlığı sorunudur ve sistemik inflamasyonla ilişkilidir. Ortalama trombosit hacmi (OTH) trombosit aktivasyonunu gösteren belirteçlerden biridir ve inflamasyonla ilişkili birçok hastalıkta yüksek bulunmuştur. KOAH\'da OTH\'nin değerlendirildiği çalışmalarda farklı sonuçlar bildirilmiştir. Bu çalışmada KOAH akut alevlenme ve stabil KOAH hastalarında C-reaktif protein (CRP), beyaz küre (BK) ve OTH\'nin değerlendirilmesi amaçlanmıştır. Yöntemler: Bu çalışmada cinsiyet ve yaş bakımından benzer 40 KOAH akut alevlenme ve 43 stabil KOAH hastası ile 40 sağlıklı bireyin verileri retrospektif olarak değerlendirildi. Bulgular: Kontrol, stabil KOAH ve KOAH akut alevlenme gruplarında ortalama OTH, CRP ve BK sırasıyla; 7,9±1,1; 8,2±1,3 ve 8,7±1,6 fL; 3,4±1,2; 5,2±3,5 ve 27,5±23,6 mg/L; 7,8±1,6; 8,1±2,1 ve 11,4±4,5 x103/ ϻL olarak bulundu. Ortalama BK ve CRP, KOAH akut alevlenme grubunda diğer iki gruba göre anlamlı yüksek bulundu (Her iki değer için p ˂0,001). Ortalama OTH, KOAH akut alevlenme grubunda diğer gruplara göre yüksek bulundu ve akut alevlenme hastalarındaki bu yüksek değer kontrol grubuna göre istatistiksel olarak anlamlıydı (p=0,030). Sonuç: Bu çalışmanın sonuçları klasik akut faz reaktanı olan CRP gibi yüksek OTH\'ninde KOAH akut alevlenmenin değerlendirilmesinde kullanılabilecek bir belirteç olabileceğini düşündürmektedir.

Anahtar Kelimeler

• C-reaktif protein, kronik obstrüktif akciğer hastalığı, ortalama trombosit hacmi, tam kan sayımı

References

1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chron- ic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347- 365.
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165- 1185.
3. Gan WQ, Man SF, Senthilselvan A, Sin DD. Associa- tion between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580.
4. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflam- matory biomarkers and exacerbations in chronic ob- structive pulmonary disease. JAMA 2013;309:2353- 2361.
5. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:37483.
6. Saldias PF, Diaz PO, Dreyse DJ,et al. Etiology and bio- markers of systemic inflammation in mild to moderate COPD exacerbations. Rev Med Chil 2012;140:10-18.
7. Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009;7:1759-1766.
8. Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab Hematol 2009;31:277-297.

9. van der Loo B, Martin JF. Megakaryocytes and plate- lets in vascular disease. Baillieres Clin Haematol 1997;10:109-123.
10. Kanbay A, Tutar N, Kaya E, et al. Mean platelet vol- ume in patients with obstructive sleep apnea syn- drome and its relationship with cardiovascular diseas- es. Blood Coagul Fibrinolysis 2013;24:532-536.
11. Arica S, Ozer C, Arica V, et al. Evaluation of the mean platelet volume in children with familial Mediterranean fever. Rheumatol Int 2012;32:3559-3563.
12. Albayrak Y, Albayrak A, Albayrak F, et al. Mean platelet volume: a new predictor in confirming acute appendicitis diagnosis. Clin Appl Thromb Hemost 2011;17:362-366.
13. Ayhan Tuzcu E, Arica S, Ilhan N, et al. Relationship between mean platelet volume and retinopathy in pa- tients with type 2 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol 2013 Aug 17 (Epub ahead of print).
14. Akgul O, Uyarel H, Pusuroglu H, et al. Prognostic value of elevated mean platelet volume in patients undergoing primary angioplasty for ST-elevation myo- cardial infarction. Acta Cardiol 2013;68:307-314.
15. Yılmaz N, Özkan OV, Büyükbaş S, et al. Mean platelet volume in patients with acute pancreatitis. J Clin Exp Invest 2011;2:362-365.
16. Steiropoulos P, Papanas N, Nena E, et al. Mean plate- let volume and platelet distribution width in patients with chronic obstructive pulmonary disease: the role of comorbidities. Angiology 2013;64:535-539.
17. Onder I, Topcu S, Dokmetas HS, et al. Platelet aggre- gation size and volume in chronic obstructive pulmo- nary disease. Mater Med Pol 1997;29:11-13.
18. Cui H, Liu L, Wei Z, et al. Clinical value of mean platelet volume for impaired cardiopulmonary function in very old male patients with chronic obstructive pulmonary disease. Arch Gerontol Geriatr 2012;54:e109-112.
19. Ulasli SS, Ozyurek BA, Yilmaz EB, Ulubay G. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary dis- ease. Pol Arch Med Wewn 2012;122:284-290.
20. Wang RT, Li JY, Cao ZG, Li Y. The Mean Platelet vol- ume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology 2013 Jun 21 (Epub ahead of print).
21. Biljak VR, Pancirov D, Cepelak I, et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets 2011;22:466-470.
22. Agusti AG, Noguera A, Sauleda J, et al. Systemic ef- fects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360.
23. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflamma- tion in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008;19:104-108.
24. Rohde G, Borg I, Wiethege A, et al. Inflammatory re- sponse in acute viral exacerbations of COPD. Infec- tion 2008;36:427-433.
25. Coban E, Adanir H. Platelet activation in patients with Familial Mediterranean Fever. Platelets 2008;19:405- 408.
26. Soydinc S, Turkbeyler IH, Pehlivan Y, et al. Mean Platelet Volume Seems To Be a Valuable Marker in Patients with Systemic Sclerosis. Inflammation 2013 Sep 1 (Epub ahead of print).
27. Rifaioglu EN, Sen BB, Ekiz O. Mean platelet volume and eosinophilia relationship in patients with bullous pemphigoid. Platelets 2013 Apr 10 (Epub ahead of print).
28. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prog- nosis of cardiovascular diseases. Int J Clin Pract 2009;63:1509-1515.
29. Ferroni P, Basili S, Martini F, et al. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Investig Med 2000;48:21-27.
30. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute ex- acerbation of COPD. Thorax 2011;66:769-774.
31. De Castro J, Hernandez-Hernandez A, Rodriguez MC, et al. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary dis- ease and asthma. Platelets 2007;18:43-51.
32. Davi G, Basili S, Vieri M, et al. Enhanced thrombox- ane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchi- tis and Haemostasis Study Group. Am J Respir Crit Care Med 1997;156:1794-1799.